<DOC>
	<DOC>NCT02215109</DOC>
	<brief_summary>The authors investigated the consecutive change of retinal vessel's diameter in affected eye and fellow eye of Branch Retinal Vein Occlusion.</brief_summary>
	<brief_title>Retinal Vessel Diameter in Branch Retinal Vein Occlusion</brief_title>
	<detailed_description>Twenty five consecutive patients who had undergone intravitreal bevacizumab injection for Branch Retinal Vein Occlusion with macular edema were included in this study. All subjects were enrolled between April, 2012 and April, 2013 in the Department of Ophthalmology, Kyungpook National University Hospital.</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>Bestcorrected visual acuity less than 20/40 Central subfield macular thickness (CSMT) 300 μm or greater on spectraldomain optical coherence tomography Patients with recurrent BRVO History of previous treatments for BRVO including vitreoretinal surgery, intravitreal injection, subtenon injection or laser photocoagulation Patients with diabetes or dyslipidemia IOP ≥ 22mmHg, treatment for glaucoma, a family history of glaucoma, or optic neuropathy High myopia (&lt;6 Diopters), high hyperopia (&gt;6 Diopters) or a history of refractive surgeries Coexisting retinal disease other than BRVO Corneal diseases include ulcer, keratoconus and a history of corneal laceration Cataract and other media opacities resulting in visual impairment or poor fundus images</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>